Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05250583
Other study ID # L-Visio-AMTRIX-TBF3
Secondary ID 2019-A03144-53
Status Terminated
Phase Phase 2
First received
Last updated
Start date June 29, 2020
Est. completion date January 7, 2021

Study information

Verified date June 2022
Source TBF Genie Tissulaire
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this open, mono center trial is to assess the impact of the use of an amniotic membrane on the healing of a keratitis resistant to medical treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date January 7, 2021
Est. primary completion date January 7, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Male or female; age between 18 and 65 years. - Patient with non-infectious keratitis resistant to medical treatment for more than 15 days or recurrent after healing treatment. - Patient with quantitative and qualitative score for inflammatory ocular signs > 20. - Patient with Oxford grade > 2. - Informed and consenting patient with a relative or friend available to instill eye drops if necessary. - Patient affiliated to a social security system or beneficiary of such a system. Exclusion Criteria: - Patient with active infectious keratitis (bacterial, parasitic or viral). - Patient with allergy to Oxybuprocaine or Tetracaine eye drops, to ester type local anesthetics and to fluorescein. - Current contact lens wear, including scleral lenses. - NSAID eye drops and any drops containing preservatives. - Antibiotic, anti-viral, anti-parasitic eye drops. - Patient with identified causes for the keratitis for which discontinuation of medical treatment beneficial. - Ocular surgery in the 3 months preceding the inclusion in the study. - Monophtalmic patient. - Person deprived of liberty by a judicial or administrative decision. - Adult subjected to a legal protection measure or unable to express his/her consent.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
LV-Visio-AMTRIX
Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit

Locations

Country Name City State
France CHU de Saint-Etienne Hôpital Nord Saint-Priest-en-Jarez

Sponsors (1)

Lead Sponsor Collaborator
TBF Genie Tissulaire

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Keratitis healing within 15 days after the beginning of the treatment Keratitis observed under slit lamp using fluorescein instillation. Keratitis considered healed if epithelialization of more than 50% and/or Oxford < grade 2 15 days
Secondary Stable or decreased score for inflammatory and clinical signs of the ocular surface Composite score for inflammatory and clinical signs of the ocular surface on 66 points. Duration and intensity are evaluated for secretion, dry eyes, tearing, foreign body sensation, fluctuating vision, photophobia, burning sensation and lids edema. Duration is evaluated from a scale from 0: never to 4: all the time. Intensity is evaluated from a scale from 0: slight to 2: severe. Localization and intensity are evaluated for conjunctival edema, conjunctival redness and neovascularization. Localization is evaluated on a scale from 0: no reaction to 4: reaction present in the whole eye. 1 day, 3 days, 5 days, 7 days, 10 days, 15 days, 30 days, 45 days
Secondary Stabilisation or decrease of pain evaluated on visual analog scale Visual Analog Scale (VAS) on 10 points from 0: no pain to 10: worst imaginable pain 1 day, 3 days, 5 days, 7 days, 10 days, 15 days, 30 days, 45 days
Secondary Preservation of epithelialization Preservation of new epithelialization evaluated under slit lamp using fluorescein instillation and Oxford grading system 15 days, 30 days, 45 days
Secondary Change in eye dryness Eye dryness evaluated by the Ocular Surface Disease Index (OSDI) (0-12 = normal; 13-22 = mild dry eye; 23-32 = moderate dry eye; >33 = severe dry eye) 15 days, 30 days, 45 days
See also
  Status Clinical Trial Phase
Completed NCT00513734 - A Comparison of Hydrogel Dressings and Ocular Lubricants in the Prevention on Corneal Damage in the Critically Ill N/A
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Recruiting NCT06229379 - The Effects of a Large Language Model on Clinical Questioning Skills N/A
Completed NCT01268306 - Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses Phase 4
Completed NCT01028027 - Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Phase 3
Recruiting NCT05432336 - Complex Ocular Infection, Optimization of Microbiological Diagnosis
Completed NCT04169061 - Impact of Acthar on Everyday Life of Participants With Severe Keratitis Phase 4
Completed NCT03237936 - Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis Phase 4
Completed NCT00001734 - Screening for NEI Clinical Studies N/A
Recruiting NCT05255016 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers Phase 2/Phase 3
Recruiting NCT05255107 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers Phase 2/Phase 3
Recruiting NCT02865876 - Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis Phase 3
Terminated NCT02116062 - Robotic Surgery of the Ocular Surface N/A
Recruiting NCT00838422 - Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound N/A
Completed NCT00949468 - Microbiological Keratitis in a Countryside City of Brazil N/A
Completed NCT03586505 - Tolerance to Light for Patients Suffering From Keratitis N/A
Recruiting NCT04420962 - Automated Quantitative Ulcer Analysis Study
Completed NCT02186431 - Contact Lenses and Infiltrative Keratitis N/A
Completed NCT05538793 - Deep Learning for the Discrimination Among Different Types of Keratits: a Nationwide Study
Not yet recruiting NCT05689996 - Ozone-based Eye Drops as Adjuvant Therapy in Microbial Keratitis Phase 3